Plan to make drugmakers shoulder "doc fix" opposed by PhRMA

11/4/2013 | Modern Healthcare (free registration)

The sustainable growth rate repeal can be paid for by pharmaceutical companies, said Sen. Jay Rockefeller, D-W.Va., referring to a measure he introduced in April. The lawmaker said his Medicare Drug Savings Act will produce savings of $141.2 billion over 10 years by returning rebate pricing to people eligible for both Medicare and Medicaid to offset the SGR repeal's cost. Seniors would not be helped and jobs could be lost by "imposing punitive policies on the biopharmaceutical research sector," PhRMA Senior Vice President Matthew Bennett said. "Instead, analysts have projected that rebates could harm Part D's competitive dynamics, yielding higher premiums, more restrictive access to medicines and diminished research on the next generation of medicines," Bennett said.

View Full Article in:

Modern Healthcare (free registration)